Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk-2256098. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 known ✓ | Q05397 | 2/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.44 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 9/20 | 0.40 |
| ▸ | JAK2 | O60674 | 8/20 | 0.40 |
| ▸ | JAK1 | P23458 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 6/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-2256098 SCHEMBL29361345 | 1.00 | PTK2 (1.00) | PTK2MAPK10MAPK9PTGS2KCNJ6 | |
| Gsk-2256098 SCHEMBL691552 | 0.99 | PTK2 (0.98) | PTK2MAPK10MAPK9PTGS2KCNJ6 | |
| Gsk-2256098 SCHEMBL691556 | 0.97 | PTK2 (0.93) | PTK2MAPK10MAPK9PTGS2KCNJ6 | |
| SCHEMBL692459 | 0.90 | PTK2 (0.82) | PTK2MAPK10MAPK9PTGS2KCNJ6 | |
| SCHEMBL691542 | 0.90 | PTK2 (0.82) | PTK2MAPK10MAPK9PTGS2KCNJ6 | |
| SCHEMBL691658 | 0.90 | PTK2 (0.82) | PTK2MAPK10MAPK9KCNJ6KCNJ5 | |
| SCHEMBL18069558 | 0.89 | PTK2 (0.81) | PTK2MAPK10MAPK9KCNJ6KCNJ5 | |
| SCHEMBL690574 | 0.89 | PTK2 (0.80) | PTK2MAPK10MAPK9KCNJ6KCNJ5 | |
| SCHEMBL692011 | 0.89 | PTK2 (0.80) | PTK2MAPK10MAPK9KCNJ6KCNJ5 | |
| SCHEMBL1293050 | 0.89 | PTK2 (0.80) | PTK2MAPK10MAPK9PTGS2KCNJ6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | claimed |
| US-20160263116-A1 | COMBINATIONS | GLAXOSMITHKLINE LLC | 2016-09-15 | — | — | US | claimed |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | TUFTS MEDICAL CENTER | 2016-09-01 | — | — | US | claimed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | claimed |
| US-20160067248-A1 | COMBINATIONS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-10 | — | — | US | claimed |
| US-9192604-B2 | Method of administration and treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-11-24 | — | — | US | claimed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | claimed |
| EP-2906215-A1 | COMBINATIONS | Glaxosmithkline LLC (US) | 2015-08-19 | — | — | EP | claimed |
| US-9012479-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2015-04-21 | — | — | US | claimed |
| WO-2015054477-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE GENERAL HOSPITAL CORPORATION (US) | 2015-04-16 | — | — | WO | claimed |
| WO-2014059095-A1 | COMBINATIONS | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | WO | claimed |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | US | claimed |
| EP-2667871-A1 | COMBINATIONS | GlaxoSmithKline Intellectual Property Limited (GB) | 2013-12-04 | — | — | EP | claimed |
| US-20130296356-A1 | COMBINATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2013-11-07 | — | — | US | claimed |
| WO-2012103276-A1 | COMBINATIONS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-08-02 | — | — | WO | claimed |
| EP-2421537-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2012-02-29 | — | — | EP | claimed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | claimed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | claimed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | claimed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263116-A1 | COMBINATIONS | PAICS, TPMT, NUP205 | PTK2 3539/4885MAPK10 4262/4885MAPK9 3958/4885 |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK10 656/4885MAPK9 386/4885 |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK10 656/4885MAPK9 386/4885 |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK10 656/4885MAPK9 386/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK10 656/4885MAPK9 386/4885 |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PTK2, BLK, BCL3 | PTK2 1/4885MAPK10 1002/4885MAPK9 734/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK10 656/4885MAPK9 386/4885 |
| US-20130296356-A1 | COMBINATIONS | CYP19A1, HSD17B11, CYP11B2 | PTK2 1414/4885MAPK10 1554/4885MAPK9 2175/4885 |
| US-20160067248-A1 | COMBINATIONS | CYP19A1, HSD17B11, CYP11B2 | PTK2 1414/4885MAPK10 1554/4885MAPK9 2175/4885 |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK10 656/4885MAPK9 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.